Blockchain Registration Transaction Record

Cancer Drug Carfilzomib May Reactivate CAR-T Therapy in Myeloma

Researchers discover Carfilzomib may restore CAR-T therapy effectiveness in multiple myeloma. Technical University of Munich study shows drug can reactivate immunotherapy when cancer cells develop resistance.

This discovery addresses a critical challenge in cancer treatment - immunotherapy resistance. For patients with advanced multiple myeloma who have stopped responding to CAR-T therapy, this research offers new hope that their treatment can be reactivated using an existing, approved drug. This could potentially extend survival and improve quality of life for patients who have exhausted other options. From a medical advancement perspective, repurposing an already-approved drug could accelerate clinical applications compared to developing entirely new treatments, potentially bringing this solution to patients more quickly. The involvement of companies like Calidi Biotherapeutics highlights the growing investment in innovative cancer therapies, suggesting this research could attract further funding and development in the field.